Mechanisms of calcification in Fahr disease and exposure of potential therapeutic targets

Publication date

2020-10

Authors

Peters, Melissa E M
de Brouwer, Esther J M
Bartstra, J. W.
Mali, WPTMISNI 0000000392849126
Koek, Huiberdina LISNI 0000000395507172
Rozemuller, Annemieke J MISNI 0000000387904725
Baas, Annette F.ISNI 0000000394578788
de Jong, Pim AORCID 0000-0003-4840-6854ISNI 0000000395539334

Editors

Advisors

Supervisors

Document Type

Article

Collections

Open Access logo

License

taverne

Abstract

Purpose of review: There is growing interest in disorders involved in ectopic mineralization. Fahr disease or idiopathic basal ganglia calcification can serve as a model for ectopic mineralization in the basal ganglia, which is fairly common in the general population. In this review, we will focus on causative gene mutations and corresponding pathophysiologic pathways in Fahr disease. Recent findings: Patients with Fahr disease have a variability of symptoms, such as movement disorders, psychiatric signs, and cognitive impairment, but can also be asymptomatic. Fahr disease is mostly autosomal dominant inherited, and there are mutations found in 4 causative genes. Mutations in SLC20A2 and XPR1 lead to a disrupted phosphate metabolism involving brain-specific inorganic phosphate transporters. Mutations in PDGFB and PDGFRB are associated with disrupted blood-brain barrier integrity and dysfunctional pericyte maintenance. In addition, the MYORG gene has recently been discovered to be involved in the autosomal recessive inheritance of Fahr. Summary: Knowledge about the mutations and corresponding pathways may expose therapeutic opportunities for patients with Fahr disease and vascular calcifications in the brain in general.

Keywords

Taverne, Clinical Neurology, Journal Article, Review

Citation

Peters, M E M, de Brouwer, E J M, Bartstra, J W, Mali, W P T M, Koek, H L, Rozemuller, A J M, Baas, A F & de Jong, P A 2020, 'Mechanisms of calcification in Fahr disease and exposure of potential therapeutic targets', Neurology: Clinical Practice, vol. 10, no. 5, pp. 449-457. https://doi.org/10.1212/CPJ.0000000000000782